- Home
- AEON vs ONFO Comparison
AEON vs ONFO Comparison
Compare AEON & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- ONFO
- Stock Information
- Founded
- AEON N/A
- ONFO 2018
- Country
- AEON United States
- ONFO United States
- Employees
- AEON N/A
- ONFO N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- ONFO Computer Software: Programming Data Processing
- Sector
- AEON Health Care
- ONFO Technology
- Exchange
- AEON Nasdaq
- ONFO Nasdaq
- Market Cap
- AEON 5.7M
- ONFO 5.8M
- IPO Year
- AEON N/A
- ONFO 2022
- Fundamental
- Price
- AEON $0.82
- ONFO $0.96
- Analyst Decision
- AEON Strong Buy
- ONFO
- Analyst Count
- AEON 1
- ONFO 0
- Target Price
- AEON $360.00
- ONFO N/A
- AVG Volume (30 Days)
- AEON 1.9M
- ONFO 9.2K
- Earning Date
- AEON 05-14-2025
- ONFO 05-16-2025
- Dividend Yield
- AEON N/A
- ONFO N/A
- EPS Growth
- AEON N/A
- ONFO N/A
- EPS
- AEON 73.23
- ONFO N/A
- Revenue
- AEON N/A
- ONFO $9,087,118.00
- Revenue This Year
- AEON N/A
- ONFO N/A
- Revenue Next Year
- AEON N/A
- ONFO N/A
- P/E Ratio
- AEON $0.01
- ONFO N/A
- Revenue Growth
- AEON N/A
- ONFO 65.97
- 52 Week Low
- AEON $0.38
- ONFO $0.61
- 52 Week High
- AEON $269.28
- ONFO $1.88
- Technical
- Relative Strength Index (RSI)
- AEON 67.31
- ONFO 43.22
- Support Level
- AEON $0.53
- ONFO $0.98
- Resistance Level
- AEON $0.85
- ONFO $1.02
- Average True Range (ATR)
- AEON 0.08
- ONFO 0.04
- MACD
- AEON 0.05
- ONFO 0.00
- Stochastic Oscillator
- AEON 92.78
- ONFO 42.86
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.